Cargando…

Anti-Müllerian Hormone Negatively Regulates Osteoclast Differentiation by Suppressing the Receptor Activator of Nuclear Factor-κB Ligand Pathway

BACKGROUND: Multiple members of the transforming growth factor-β (TGF-β) superfamily have well-established roles in bone homeostasis. Anti-Müllerian hormone (AMH) is a member of TGF-β superfamily of glycoproteins that is responsible for the regression of fetal Müllerian ducts and the transcription i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jung Ha, Yang, Yong Ryoul, Kwon, Ki-Sun, Kim, Nacksung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Bone and Mineral Research 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441534/ https://www.ncbi.nlm.nih.gov/pubmed/34520656 http://dx.doi.org/10.11005/jbm.2021.28.3.223

Ejemplares similares

NRROS Negatively Regulates Osteoclast Differentiation by Inhibiting RANKL-Mediated NF-κB and Reactive Oxygen Species Pathways
por: Kim, Jung Ha, et al.
Publicado: (2015)

Signaling Pathways in Osteoclast Differentiation
por: Kim, Jung Ha, et al.
Publicado: (2016)

Regulation of NFATc1 in Osteoclast Differentiation
por: Kim, Jung Ha, et al.
Publicado: (2014)

Overexpression of Neurogenin 1 Negatively Regulates Osteoclast and Osteoblast Differentiation
por: Kim, Jung Ha, et al.
Publicado: (2022)

Tusc2/Fus1 regulates osteoclast differentiation through NF-κB and NFATc1
por: Kim, Inyoung, et al.
Publicado: (2017)

LIM Homeobox Transcription Factor 1-β Expression is Upregulated in Patients with Osteolysis after Total Ankle Arthroplasty and Inhibits Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclast Differentiation in Vitro
por: Kim, Kabsun, et al.
Publicado: (2022)

Humanin suppresses receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation via AMP-activated protein kinase activation
por: Kang, Namju, et al.
Publicado: (2019)

Rev-erbα Negatively Regulates Osteoclast and Osteoblast Differentiation through p38 MAPK Signaling Pathway
por: Kim, Kabsun, et al.
Publicado: (2020)

IRF2 enhances RANKL-induced osteoclast differentiation via regulating NF-κB/NFATc1 signaling
por: Kim, Inyoung, et al.
Publicado: (2021)

The IRF2BP2-KLF2 axis regulates osteoclast and osteoblast differentiation
por: Kim, Inyoung, et al.
Publicado: (2019)

Inhibitory Effect of Biotransformed-Fucoidan on the Differentiation of Osteoclasts Induced by Receptor for Activation of Nuclear Factor-κB Ligand
por: Park, Bobae, et al.
Publicado: (2022)

Extracts of Flavoparmelia sp. Inhibit Receptor Activator of Nuclear Factor-κB Ligand-Mediated Osteoclast Differentiation
por: Kim, Kwang-Jin, et al.
Publicado: (2019)

Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo
por: Baek, Jong Min, et al.
Publicado: (2016)

Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation in vitro
por: Baek, Jong Min, et al.
Publicado: (2017)

Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors
por: Kim, Jang Heub, et al.
Publicado: (2014)

Adrenomedullin inhibits osteoclast differentiation through the suppression of receptor activator of nuclear factor-κB ligand-induced nuclear factor-κB activation in glucocorticoid-induced osteoporosis
por: Liu, Yuanxin, et al.
Publicado: (2017)

The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor in myoma and adenomyosis
por: Kim, Shin Young, et al.
Publicado: (2018)

Anti-Müllerian Hormone Signal Transduction involved in Müllerian Duct Regression
por: Cate, Richard L.
Publicado: (2022)

Clinical Utilities of Anti-Müllerian Hormone
por: Russell, Nicole, et al.
Publicado: (2022)

The ATF3–OPG Axis Contributes to Bone Formation by Regulating the Differentiation of Osteoclasts, Osteoblasts, and Adipocytes
por: Kim, Jung Ha, et al.
Publicado: (2022)

Towards international standardization of immunoassays for Müllerian inhibiting substance/anti-Müllerian hormone
por: Ferguson, Jackie MC, et al.
Publicado: (2018)

Decreased Anti-Müllerian hormone and Anti-Müllerian hormone receptor type 2 in hypothalami of old Japanese Black cows
por: KEREILWE, Onalenna, et al.
Publicado: (2020)

Involvement of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-induced Incomplete Cytokinesis in the Polyploidization of Osteoclasts
por: Takegahara, Noriko, et al.
Publicado: (2016)

Anti-Mullerian Hormone: Usefulness in Clinical Practice
por: Buhling, Kai J., et al.
Publicado: (2013)

Clinical Utility of Anti-Mullerian Hormone in Pediatrics
por: Kanakatti Shankar, Roopa, et al.
Publicado: (2021)

The roles of anti-Müllerian hormone in breast cancer
por: Chen, Xuan, et al.
Publicado: (2023)

A Novel Member of the Leukocyte Receptor Complex Regulates Osteoclast Differentiation
por: Kim, Nacksung, et al.
Publicado: (2002)

Müllerian Duct Anomalies and Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome
por: Yang, Min, et al.
Publicado: (2023)

Clinical application of anti-Müllerian hormone as a predictor of controlled ovarian hyperstimulation outcome
por: Lee, Jae Eun, et al.
Publicado: (2012)

MicroRNA-26a Regulates RANKL-Induced Osteoclast Formation
por: Kim, Kabsun, et al.
Publicado: (2015)

Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery
por: Kim, Hyun-Ah, et al.
Publicado: (2018)

Functional profiles of Müllerian inhibiting substance/anti-Müllerian hormone (MIS/AMH) in primarily cultured endometrial cancer cells
por: Kim, Sang Il, et al.
Publicado: (2021)

The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome
por: Sivanandy, Mala S., et al.
Publicado: (2023)

α-Tocopheryl Succinate Inhibits Osteoclast Formation by Suppressing Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL) Expression and Bone Resorption
por: Kim, Ha-Neui, et al.
Publicado: (2012)

Fexaramine Inhibits Receptor Activator of Nuclear Factor-κB Ligand-induced Osteoclast Formation via Nuclear Factor of Activated T Cells Signaling Pathways
por: Zheng, Ting, et al.
Publicado: (2017)

Placotylene A, an Inhibitor of the Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclast Differentiation, from a Korean Sponge Placospongia sp.
por: Kim, Hiyoung, et al.
Publicado: (2014)

Application of serum anti-Müllerian hormone levels in selecting patients with polycystic ovary syndrome for in vitro maturation treatment
por: Seok, Hyun Ha, et al.
Publicado: (2016)

Anti-Mullerian-hormone levels during pregnancy and postpartum
por: Köninger, Angela, et al.
Publicado: (2013)

Clinical application of serum anti-Müllerian hormone in women
por: Oh, So Ra, et al.
Publicado: (2019)

Anti-Müllerian Hormone Expression in Endometrial Cancer Tissue
por: Gowkielewicz, Marek, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v49al8igmpfk3rclauish6mmp3